Literature DB >> 8176644

Risk factors for anal human papillomavirus infection and anal cytologic abnormalities in HIV-positive and HIV-negative homosexual men.

J M Palefsky1, S Shiboski, A Moss.   

Abstract

Men with advanced human immunodeficiency virus (HIV) disease have a high prevalence of anal human papillomavirus (HPV) infection and potentially precancerous anal disease. To characterize prevalence of and risk factors for anal HPV infection and anal cytologic abnormalities, 37 HIV-positive and 28 HIV-negative participants in the San Francisco General Hospital Cohort Study were studied. A questionnaire was administered, followed by an anal examination consisting of two consecutive anal swabs for cytology and HPV DNA hybridization, and anoscopy with biopsy of visible lesions. Ten of 28 (36%) HIV-negative men and 19 of 37 (51%) HIV-positive men had anal HPV infection (p = 0.32). Risk factors for anal HPV infection included HIV positivity with a CD4 count < 200/mm3 (p = 0.03) and a history of smoking (p = 0.03). Abnormal anal cytology was found in 2 of 26 (8%) HIV-negative men and 10 of 36 (28%) HIV-positive men with cytology adequate for interpretation (p = 0.09). Risk factors for abnormal anal cytology included HIV positivity with a CD4 count < 200/mm3 (p = 0.006) and current smoking (p = 0.03). We conclude that the risk of development of anal disease and HPV infection was highest among HIV-positive men with a CD4 count of < 200/mm3, and that smoking may play a role in the pathogenesis of anal disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8176644

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  25 in total

1.  [Anal HPV infections].

Authors:  Felix Aigner; Friedrich Conrad; Andreas Widschwendter; Robert Zangerle; Bettina Zelger; Alfred Haidenberger; Sebastian Roka; Kurt Heim; Reinhard Höpfl; Martin Klimpfinger; Yves Marcus Rigler; Hugo Bonatti; Johann Pfeifer; Andrea Maier; Reinhard Kirnbauer; Andreas Salat
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

Review 2.  Anal human papillomavirus and anal cancer.

Authors:  P Tilston
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

3.  Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease.

Authors:  J M Palefsky; E A Holly; M L Ralston; S P Arthur; C J Hogeboom; T M Darragh
Journal:  Genitourin Med       Date:  1997-06

Review 4.  Cigarette smoking in the HIV-infected population.

Authors:  Shiva Rahmanian; Mary Ellen Wewers; Susan Koletar; Nancy Reynolds; Amy Ferketich; Philip Diaz
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 5.  Smoking and HIV: prevalence, health risks, and cessation strategies.

Authors:  Alan R Lifson; Harry A Lando
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

6.  Prevalence of Anal Dysplasia in Human Immunodeficiency Virus-Infected Transgender Women.

Authors:  Takaaki Kobayashi; Keith Sigel; Michael Gaisa
Journal:  Sex Transm Dis       Date:  2017-11       Impact factor: 2.830

7.  A study of anal intraepithelial neoplasia in HIV positive homosexual men.

Authors:  H B Lacey; G E Wilson; P Tilston; E G Wilkins; A S Bailey; G Corbitt; P M Green
Journal:  Sex Transm Infect       Date:  1999-06       Impact factor: 3.519

Review 8.  The impact of smoking on HPV infection and the development of anogenital warts.

Authors:  Reto Kaderli; Beat Schnüriger; Lukas E Brügger
Journal:  Int J Colorectal Dis       Date:  2014-06-17       Impact factor: 2.571

Review 9.  Social Inequalities in Palliative Care for Cancer Patients in the United States: A Structured Review.

Authors:  Ronit Elk; Tisha M Felder; Ebru Cayir; Cleo A Samuel
Journal:  Semin Oncol Nurs       Date:  2018-08-23       Impact factor: 2.315

10.  Risk factors for anal human papillomavirus infection type 16 among HIV-positive men who have sex with men in San Francisco.

Authors:  Alexandra L Hernandez; Jimmy T Efird; Elizabeth A Holly; J Michael Berry; Naomi Jay; Joel M Palefsky
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.